{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T03:01:03Z","timestamp":1725159663798},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jprot.2014.12.015","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T02:40:05Z","timestamp":1420684805000},"page":"59-67","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A signature for immune response correlates with HCV treatment outcome in Caucasian subjects"],"prefix":"10.1016","volume":"116","author":[{"given":"Brian J.","family":"Hare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Haseltine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Chelsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Allard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyn","family":"Botfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2014.12.015_bb0005","author":"World Health Organization"},{"key":"10.1016\/j.jprot.2014.12.015_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in the United States","volume":"9","author":"Davis","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jprot.2014.12.015_bb0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0020","series-title":"Randomised trial of interferon alpha2b plus ribavirin for 48weeks or for 24weeks versus interferon alpha2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus","first-page":"352","author":"Poynard","year":"1998"},{"key":"10.1016\/j.jprot.2014.12.015_bb0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1373\/clinchem.2006.070961","article-title":"A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C","volume":"52","author":"Ngo","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.jprot.2014.12.015_bb0035","series-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","first-page":"55","author":"Guidelines","year":"2011"},{"key":"10.1016\/j.jprot.2014.12.015_bb0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2014.12.015_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jprot.2014.12.015_bb0050","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"Sarasin-Filipowicz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jprot.2014.12.015_bb0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.24284","article-title":"High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients","volume":"53","author":"Patel","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jprot.2014.12.015_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152606776056706","article-title":"Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease","volume":"6","author":"Lin","year":"2006","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.jprot.2014.12.015_bb0070","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0075","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV Genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2012.10.019","article-title":"Perspectives and challenges of interferon-free therapy for chronic hepatitis C","volume":"58","author":"Lange","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"12-Week interferon-free regimen of ABT-450\/R+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and in 47% of previous non-responders","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0090","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0095","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S1535-9476(20)31935-6","article-title":"The human liver proteome project","volume":"6","author":"Beretta","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jprot.2014.12.015_bb0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/cis510","article-title":"Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions","volume":"55","author":"Liu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jprot.2014.12.015_bb0115","doi-asserted-by":"crossref","first-page":"e39603","DOI":"10.1371\/journal.pone.0039603","article-title":"Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study","volume":"7","author":"Gangadharan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2014.12.015_bb0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0168-8278(96)80076-6","article-title":"Elevated serum levels of 90K\/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients","volume":"25","author":"Artini","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0125","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jprot.2014.12.015_bb0130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2008.12.010","article-title":"Alteration of protein glycosylation in liver diseases","volume":"50","author":"Blomme","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0135","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0016-5085(94)90550-9","article-title":"Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C","volume":"107","author":"Mosnier","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jprot.2014.12.015_bb0140","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ceb.2011.11.001","article-title":"Structure and function of focal adhesions","volume":"24","author":"Wehrle-Haller","year":"2012","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0145","doi-asserted-by":"crossref","first-page":"10714","DOI":"10.1074\/jbc.M111.299594","article-title":"Kindlin-3 mediates integrin \u03b1L\u03b22 outside-in signaling, and it interacts with scaffold protein receptor for activated-C kinase 1 (RACK1)","volume":"287","author":"Feng","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jprot.2014.12.015_bb0150","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1073\/pnas.96.15.8693","article-title":"A heterozygous mutation of beta-actin associated with neutrophil dysfunction and recurrent infection","volume":"96","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jprot.2014.12.015_bb0155","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1038\/onc.2011.161","article-title":"A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility","volume":"30","author":"Leung","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jprot.2014.12.015_bb0160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.freeradbiomed.2012.01.008","article-title":"Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations","volume":"52","author":"Choi","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/msb.2008.66","article-title":"Hepatitis C virus infection protein network","volume":"4","author":"De Chassey","year":"2008","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jmb.2011.03.076","article-title":"Focal adhesion proteins talin-1 and vinculin negatively affect paxillin phosphorylation and limit retroviral infection","volume":"410","author":"Brown","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jprot.2014.12.015_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-5956-8-12","article-title":"Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins","volume":"8","author":"Zhang","year":"2010","journal-title":"Proteome Sci"},{"key":"10.1016\/j.jprot.2014.12.015_bb0180","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/clinchem\/32.8.1563","article-title":"Decreased activity of carnosinase in serum of patients with chronic liver disorders","volume":"32","author":"Bando","year":"1986","journal-title":"Clin Chem"},{"key":"10.1016\/j.jprot.2014.12.015_bb0185","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/onc.2010.258","article-title":"AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-\u03b2-mediated ERK signaling","volume":"29","author":"Kong","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jprot.2014.12.015_bb0190","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/pros.21381","article-title":"Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer","volume":"71","author":"Yip","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.jprot.2014.12.015_bb0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1479-5876-10-106","article-title":"Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis","volume":"10","author":"Huang","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-8-64","article-title":"JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma","volume":"8","author":"Chang","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jprot.2014.12.015_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1515\/CCLM.2000.029","article-title":"Serum protein 90K\/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection","volume":"38","author":"Kittl","year":"2000","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jprot.2014.12.015_bb0210","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkr988","article-title":"KEGG for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Kanehisa","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jprot.2014.12.015_bb0215","doi-asserted-by":"crossref","first-page":"D54","DOI":"10.1093\/nar\/gki031","article-title":"Entrez Gene: gene-centered information at NCBI","volume":"33","author":"Maglott","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jprot.2014.12.015_bb0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jprot.2014.12.015","article-title":"A signature for immune response correlates with HCV treatment outcome in Caucasian subjects","volume":"116","author":"Hare","year":"2015","journal-title":"J Proteomics"}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391915000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391915000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T09:33:15Z","timestamp":1650965595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391915000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":43,"alternative-id":["S1874391915000032"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2014.12.015","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A signature for immune response correlates with HCV treatment outcome in Caucasian subjects","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2014.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}